Side effects and management of side effects of methotrexate in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Albrecht, K ^a   Muller Ladner U ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Methotrexate; Rheumatoid arthritis; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; HYDROXYCHLOROQUINE; INFLUENZA VACCINE; LIVE VACCINE; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PNEUMOCOCCUS VACCINE; PREDNISONE; SALAZOSULFAPYRIDINE; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR INHIBITOR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE;

ABORTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BACTERIAL INFECTION; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARCINOGENICITY; CLINICAL PROTOCOL; COHORT ANALYSIS; CONGENITAL MALFORMATION; CRYPTOCOCCOSIS; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY COUGH; ELECTIVE SURGERY; EVENING DOSAGE; FATIGUE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART TAMPONADE; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; IMMUNIZATION; IMPOTENCE; INFECTION; INFERTILITY; INFLAMMATION; INFLUENZA VACCINATION; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIBIDO DISORDER; LISTERIOSIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER ENZYME BLOOD LEVEL; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MEMORY DISORDER; MENSTRUATION DISORDER; META ANALYSIS (TOPIC); MOOD DISORDER; MOUTH ULCER; MYALGIA; NAUSEA; NEOPLASM; NEPHROTOXICITY; NOCARDIOSIS; NODULOSIS; OOCYTE DEVELOPMENT; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PERICARDIAL SEROSITIS; PERICARDITIS; PERIOPERATIVE PERIOD; PHOTOSENSITIVITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SIDE EFFECT; SMALLPOX; SPERMATOGENESIS; STOMACH ULCER; STOMATITIS; STRESS FRACTURE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT DURATION; UROGENITAL TRACT DISEASE; VAGINA DISCHARGE; VASCULITIS; VERTIGO; VITAMIN SUPPLEMENTATION; VOMITING; WOUND HEALING; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COUGHING; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; HEADACHE; OSTEOSCLEROSIS; RASH; SKIN NODULE; UROGENITAL TRACT MALFORMATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650528500     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
2. MAETZEL A, WONG A, STRAND V, TUG WELL P, WELLS G, BOMBARDIER C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving diseasemodifying anti-rheumatic drugs. Rheumatology 2000;39:975-81.
3. SCHNABEL A, REINHOLD-KELLER E, WILLMANN V, GROSS WL: Tolerability of methotrexate starting with 15 or 25mg/week for rheumatoid arthritis. Rheumatol Int 1994;14:33-8. (Pubitemid 24189748)
4. RHEUMATOID ARTHRITIS CLINICAL TRIAL ARCHIVE GROUP: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995;22:218-23.
5. SALLIOT C, van der HEIJDE D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-04.
6. WEINBLATT ME, TRENTHAM DE, FRASER PA et al.: Long-term prospective trial of lowdose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167-75.
7. GISPEN JG, ALARCON GS, JOHNSON JJ, ACTON RT, BARGER BO, KOOPMAN WJ: Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1987;14:74-9.
8. KREMER JM, PHELPS CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
9. SCHNABEL A, HERLYN K, BURCHARDI C, REINHOLD-KELLER E, GROSS WL: Longterm tolerability of methotrexate at doses exceeding 15mg per week in rheumatoid arthritis. Rheumatol Int 1996;15:195-200.
10. RAU R, SCHLEUSSER B, HERBORN G, KARGER T: Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-9.
11. KINDER AJ, HASSELL AB, BRAND J, BROWNHELD A, GROVE M, SHADFORTH MF: The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 2005;44:61-6.
12. KUITUNEN T, MALMSTROM J, PALVA E, PETTERSON T: Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol 2005;34:238-41.
13. BERTHELOT JM, MAUGARS Y, HAMIDOU M et al.: Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight casereports and a review of one hundred cases from the literature (with twenty-four deaths). Rev Rhum Engl Ed 1995;62:477-86.
14. HALLA JT, HARDIN JG: Underrecognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. J Rheumatol 1994;21:1224-6.
15. MOHYUDDIN T, ELYAN M, KUSHNER I: Pericarditis: a rare complication of methotrexate therapy. Clin Rheumatol 2007;26:2157-8.
16. ABU-SHAKRA M, NICOL P, UROWITZ MB: Accelerated nodulosis, pleural effusion and pericardial tamponade during methotrexate therapy. J Rheumatol 1994;21:934-7.
17. PHAM T, GOSSEC L, CONSTANTIN A et al.: Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:379-87.
18. REISS AB, CARSONS SE, ANWAR K et al.: Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58:3675-83.
19. INCE A, YAZICI Y, AMURYUDAN V, YAZICI H: The frequency and characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): a masked and controlled study. Clin Rheumatol 1996;15:491-4.
20. PASTOR-NIETO MA, KILMURRAY LG, LOPEZ-CHUMILLAS A et al.: Methotrexate-associated lymphoproliferative disorder presenting as oral ulcers in a patient with rheumatoid arthritis. Adas Dermosifiliogr 2009;100:142-6.
21. SEGAL R, CASPI D, TISHLER M, FISHEL B, YARON M: Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988;31:1182-5.
22. KERSTENS PJ, BOERBOOMS AM, JEURISSEN ME, FAST JH, ASSMANN KJ, VAN DE PUTTE LB: Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol 1992;19:867-71.
23. DASH S, SEIBOLD JR, TIKU ML: Successful treatment of methotrexate induced nodulosis with D-penicillamine. J Rheumatol 1999;26:1396-9.
24. MCKENDRY RJ, DALE P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6. (Pubitemid 24031586)
25. NAKAZAKI S, MURAYAMA T, KATOH S: Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Ryumachi 2001;41:929-37.
26. BOURRE-TESSIER J, HARAOUI B: Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic Review. J Rheumatol 2010; Epub ahead of print.
27. WHITE DH, CHAPMAN PT, OTJONNELL JL, JAMES J, FRAMPTON C, STAMP LK: Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Intern Med J 2009; epub ahead of print.
28. VISSER K, VAN DER HEIJDE DM: Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009;27:1017-25.
29. YAZICI Y, ERKAN D, HARRISON MJ, NIKOLOV NP, PAGET SA: Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005;23:517-20.
30. CURTIS JR, BEUKELMANN T, ONOFREI A et al.: Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69:43-7.
31. PAVY S, CONSTANTIN A, PHAM T et al.: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388-95.
32. KREMER JM, ALARCON GS, LIGHTFOOT RW et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
33. MCLEAN-TOOKE A, ALDRIDGE C, WAUGH S, SPICKETT GP, KAY L: Methotrexate, rheumatoid arthritis and infection risk - what is the evidence? Rheumatology 2009;48:867-71.
34. SANY J, ANAYA JM, CANOVAS F et al.: Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993;20:1129-32.
35. PIERINGER H, STUBY U, BIESENBACH G: The place of methotrexate perioperatively in the elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:1217-20.
36. ZONNEVELD IM, BAKKER WK, DIJKSTRA PF, BOS JD, VAN SOESBERGEN RM, DINANT HJ: Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132:184-7.
37. PRESTON SJ, DIAMOND T, SCOTT A, LAURENT MR: Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993;52:582-5.
38. WERNICK R, SMITH DL: Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989;32:770-5.
39. WEINSTOCK-GUTTMANN B, NAIR D, COHEN JA: Neurologic complications of immunosuppressive and anti-inflammatory therapy for rheumatic diseases. J Clin Rheumatol 1996;2:268-78.
40. SOMMER WH, GANIERE V, GACHOUD D et al.: Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. Scand J Rheumatol 2008;37:306-9.
41. SARAVANAN V, KELLY CA: Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 2004;43:143-7.
42. GOLDEN MR, KATZ RS, BALK RA, GOLDEN HE: The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995;22:1043-7.
43. OHOSONE Y, OKANO Y, KAMEDA H et al.: Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997;24:2299-303.
44. TOKUDA H, SAKAI F, YAMADA H et al.: Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008;47:915-23.
45. LEWDEN B, VIAL T, ELEFANT E, NELVA A, CARLIER P, DESCOTES J: Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004;31:2360-5.
46. MARTINEZ LOPEZ JA, LOZA E, CARMONA L: Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678-84.
47. BEAUPARLANT P, PAPP K, HARAOUI B: The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:148-58.
48. RIZZI R, CURCI P, DELIA M et al.: Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 2009;26:1-9.
49. ORTIZ Z, SHEA B, SUAREZ-ALMAZOR ME, MOHER D, WELLS GA, TUGWELL P: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
50. PREY S, PAULC: Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009;160:622-8.